On-X trial could expand valve's use
This article was originally published in Clinica
Executive Summary
Austin, Texas-based On-X Life Technologies has completed enrolment in the high-risk aortic valve replacement patient group in a trial of its mechanical heart valve. If the trial is successful, the On-X valve may become the only mechanical heart valve that does not require recipients to take large quantities of anticoagulant medication.
You may also be interested in...
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.
Roche Steals A March In B-cell Lymphoma
New data on Columvi could allow the bispecific’s use as an earlier treatment, giving it a three-year head start on AbbVie and Genmab’s Epkinly.